Stryker Corporation $SYK Shares Sold by Candriam S.C.A.

Candriam S.C.A. lowered its position in shares of Stryker Corporation (NYSE:SYK) by 2.3% in the second quarter, HoldingsChannel.com reports. The firm owned 179,077 shares of the medical technology company’s stock after selling 4,190 shares during the quarter. Candriam S.C.A.’s holdings in Stryker were worth $70,851,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Brighton Jones LLC raised its position in shares of Stryker by 15.4% during the 4th quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company’s stock worth $1,643,000 after acquiring an additional 609 shares in the last quarter. CWM LLC increased its stake in Stryker by 3.0% in the first quarter. CWM LLC now owns 17,370 shares of the medical technology company’s stock valued at $6,466,000 after purchasing an additional 513 shares during the last quarter. Edgestream Partners L.P. raised its holdings in Stryker by 27.0% during the first quarter. Edgestream Partners L.P. now owns 893 shares of the medical technology company’s stock worth $332,000 after purchasing an additional 190 shares in the last quarter. OVERSEA CHINESE BANKING Corp Ltd lifted its position in shares of Stryker by 58.3% during the 1st quarter. OVERSEA CHINESE BANKING Corp Ltd now owns 888 shares of the medical technology company’s stock worth $331,000 after buying an additional 327 shares during the last quarter. Finally, First Command Advisory Services Inc. purchased a new stake in shares of Stryker during the 1st quarter worth approximately $152,000. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Insiders Place Their Bets

In other Stryker news, Director Ronda E. Stryker sold 276,173 shares of the business’s stock in a transaction on Thursday, November 6th. The shares were sold at an average price of $353.28, for a total value of $97,566,397.44. Following the transaction, the director directly owned 2,702,108 shares of the company’s stock, valued at approximately $954,600,714.24. The trade was a 9.27% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Viju Menon sold 500 shares of the company’s stock in a transaction on Monday, August 25th. The stock was sold at an average price of $390.61, for a total transaction of $195,305.00. Following the transaction, the insider owned 12,511 shares of the company’s stock, valued at approximately $4,886,921.71. The trade was a 3.84% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 520,500 shares of company stock worth $184,803,065. 5.20% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

SYK has been the topic of several research analyst reports. Rothschild Redb upgraded shares of Stryker to a “hold” rating in a research note on Thursday, September 18th. Redburn Partners set a $420.00 target price on Stryker in a research report on Thursday, September 18th. Wall Street Zen raised Stryker from a “hold” rating to a “buy” rating in a research report on Saturday, October 18th. Weiss Ratings downgraded Stryker from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Friday, November 7th. Finally, Evercore ISI cut their price target on Stryker from $410.00 to $405.00 and set an “outperform” rating on the stock in a research report on Friday, October 31st. Thirteen equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $433.37.

Stryker Stock Performance

NYSE SYK opened at $367.65 on Thursday. The firm has a market cap of $140.60 billion, a P/E ratio of 48.70, a P/E/G ratio of 2.66 and a beta of 0.94. Stryker Corporation has a 52-week low of $329.16 and a 52-week high of $406.19. The business’s 50-day moving average price is $372.98 and its 200 day moving average price is $381.24. The company has a quick ratio of 1.06, a current ratio of 1.78 and a debt-to-equity ratio of 0.70.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Thursday, October 30th. The medical technology company reported $3.19 EPS for the quarter, beating the consensus estimate of $3.13 by $0.06. Stryker had a return on equity of 23.94% and a net margin of 12.25%.The firm had revenue of $6.06 billion during the quarter, compared to the consensus estimate of $6.04 billion. During the same period in the prior year, the business earned $2.87 EPS. The firm’s revenue was up 10.2% compared to the same quarter last year. Stryker has set its FY 2025 guidance at 13.500-13.600 EPS. On average, equities research analysts expect that Stryker Corporation will post 13.47 earnings per share for the current year.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.